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There is a now a wealth of epidemiological, animal, and clinical data to suggest the beneﬁts of uric acid reduction and xanthine
oxidase inhibition in prevention of vascular disease. This review discusses the available epidemiological, preclinical, and clinical
data and considers arguments for and against a role for serum uric acid in common cardiovascular disorders. It concludes that
large scale trials with clinical endpoints are justiﬁed to address this important question and to deﬁne whether use of drugs such as
allopurinol should be a routine part of preventative strategies.
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1.Introduction
Xanthine oxidase inhibitors are typically used in the treat-
ment of gout and nephropathy and renal stone diseases
linked to hyperuricaemia. There has been recent interest in
the potential beneﬁt of these agents in the prevention of
vascular disease, including those aﬀecting the cerebrovascu-
lature. This interest has been driven by emerging evidence
suggesting a role for serum uric acid in the development of
cardiovascular disease and because xanthine oxidase inhibi-
tion may yield ancillary beneﬁts over uric acid reduction;
the enzyme is an important source of oxidative stress in the
vasculature.
In this review we summarise available epidemiological,
preclinical, and clinical data and consider arguments for and
against a role for serum uric acid in common cardiovascular
and cerebrovascular disorders. Against this background
we also discuss the potential beneﬁt of xanthine oxidase
inhibition as a vascular preventative strategy.
2.UricAcidandXanthineOxidase?
Uric acid is a breakdown product of ingested and endoge-
nouslysynthesisedpurines.DNAandRNAaredegradedinto
purine nucleotides and bases, which are then metabolised,
via the action of xanthine oxidase, to xanthine and then
uric acid. Xanthine oxidase is from the molybendum iron-
sulfur ﬂavin hydroxylase group of enzymes and is found
predominantly in the liver and gastrointestinal tract but
also in the kidney and brain. Interestingly, it is also found
throughout the cardiovascular system [1], and endothelial
bound forms have been described. Expression of these has
been shown to increase in ischaemia and in response to
increased levels of proinﬂammatory cytokines [2]. While
the major role of xanthine oxidase is conversion of hypox-
anthine and xanthine to uric acid, an interconvertible
form, xanthine dehydrogenase, also exists and is responsible
for conversion of NAD+ to NADH [3]. The action of
these enzymes yields hydroxyl free radicals and hydrogen
peroxide which can add to or initiate oxidative stress
[4].
In most mammals, the enzyme uricase further oxidizes
uric acid to allantoin, which is then excreted in the urine. In
humans and higher primates however, uric acid undergoes
no further metabolism and homeostasis relies upon excre-
tion of uric acid, predominantly via the kidneys. Levels are
thus higher, and humans also have the ability to reabsorb
uric acid in the proximal tubule, via the action of a urate
transporter [21]. While uric acid levels can be increased
by rare enzymatic defects, states of high cell turnover and
alcohol ingestion [22, 23], the majority of cases of elevated
serum uric acid, and the population distribution of levels
result from diﬀerences in renal excretion.2 Cardiovascular Psychiatry and Neurology
Table 1: The relationship between serum uric acid and vascular outcomes.
Ref Population Change in outcome measure
[5] Acute stroke RR 1.27 (1.18–1.36)
a for recurrent vascular events
[6] Acute stroke Serum uric acid ↑ in those with early clinical deterioration (P = .001)
[7] Acute Stroke OR 1.37 (1.13–1.67) for early death
b
[8] Acute Stroke OR 1.12 (1–1.25) per additional mg/dL uric acid for good outcome
[7] Acute Stroke OR 1.57 (1.02–2.42) for poor outcome∗
[9] Diabetes HR 1.91 (1.24–2.94) for stroke
b
[10] Diabetes and stroke HR 1.49 (1.21–1.84) for recurrent CV eventa
[11] Coronary Disease HR 1.5 (1.02–2.1) for all cause mortality
b
[12] Coronary Disease HR 1.23 (1.11–1.36) for all cause mortality
c
[13] Hypertension HR 1.32 (1.03–1.69), for CV eventsb
[14] Hypertension HR 1.22 (1.11–1.35) for CV disease
d
[15] Hypertension HR 1.14 (1.02–1.27) for CV mortality
e HR 1.34 (1.14–1.57) for fatal stroke
e
[16] Hypertension HR 1.73 (1.01–3) for CV event ratesb
[17] Hypertension HR 1.03 (0.93–1.14) for CV mortality
e HR 1.06 (0.99–1.13) for all CV eventse
[18] Healthy Volunteers HR 1.16 (P<. 001) for all-cause mortality
b HR 1.35 (P = .02) for ischaemic stroke
b
[19] Healthy Volunteers HR 1.35 (1.20–1.52) for CV mortality
b HR 1.37 (1.09–1.74) for stroke
b
[20] Healthy Volunteers OR 2.6 (1.2–5.4) for white matter hyperintense signals on MRI imaging
b
Resultsexpressedasratioand95%CI. a peradditional0.1mmol/Linserumuricacid, b forhighestversuslowestgroup, c,d peradditional0.6and0.86mmol/L
in serum uric acid respectively, e for each 50µmol/L increment in serum uric acid. ∗on univaiate analysis. RR—Relative risk, OR—Odds ratio, HR—Hazard
ratio, CV—Cardiovascular.
The reason for this diﬀerence in humans is unclear and
whether this was a protective and beneﬁcial change will be
d i s c u s s e di nm o r ed e t a i ll a t e r[ 24].
3. IsUric Acida Risk Factor—Epidemiology?
Most epidemiological studies associate increasing serum uric
acid with increased cardiovascular event rate and mortality
in those with known or elevated risk of vascular disease
and amongst healthy volunteers. These data have been
thoroughly reviewed elsewhere [25] but are summarised in
Table 1. Of interest, the relationship with stroke rate and
mortalityhasoftenbeenlessclear.Forexample,inthosewith
hypertension, many studies have not speciﬁcally evaluated
stroke mortality or have been limited by low observed stroke
rates [16, 26]. As an example, one Chinese study has shown
a strong association [15] while others have not [13, 17]. An
association has been seen with stroke risk in patients with
diabetes [9] and in a large observational cohort of patients
aged >55 years of age, although the association was less
prominentinhypertensiveindividuals[27].Arecentanalysis
of hypertensive individuals, in which there were 354 stroke
deaths (the highest number in any study to date), showed
that there was indeed a link between increasing serum
uric acid and stroke mortality but that this relationship
was J-shaped, unlike the signiﬁcant linear relationships seen
between uric acid and total vascular and coronary mortality
[28].
Thereisalsocontroversyconcerningtheimpactofserum
uric acid on outcome in the acute period after stroke where
antioxidant activity could be considered highly beneﬁcial,
as discussed later. In a large study of those with acute
stroke, increasing serum uric acid levels was associated with
a reduced likelihood of favourable outcome at 90 days (odds
ratio 0.78, 95% CI 0.67–0.91 per additional 0.1mmol/L uric
acid) and an increased risk of recurrent vascular events [5].
This association was more prominent in those with diabetes
[10]. Others have suggested increased risk of early clinical
deterioration following ischaemic stroke [6] in those with
increased serum uric acid level. However, in contrast, a
further study reported conﬂicting results: in 800 patients
with acute ischaemic stroke, increasing uric acid levels was
associated with a good outcome (odds ratio 1.12, 95% CI
1–1.25 per additional mg/dL uric acid) at seven days [8]. A
recent analysis from our unit however, found that increasing
uric acid levels did link with increased odds of poor outcome
(but not in an independent fashion), and there was no
evidencethatincreasingserumuricacidconveyedprotection
to the ischaemic brain [7] and others have recently shown
increased risk of death early after stroke [29].
4.UricAcidIs Harmful
Uric acid crystals clearly have the potential to induce
inﬂammationgiventheirroleinpathogenesisofgout.Serum
uric acid levels have also been linked to levels of proin-
ﬂammatory cytokines and may have a role in perpetuating
the inﬂammatory response that characterises atherosclerosis.
Uric acid may also increase oxygenation of LDL [30], and
uric acid crystals have also have been shown to stimulate
release of the platelet constituents serotonin, ATP and ADP
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Uric acid has been shown to stimulate rat vascular
smooth muscle production in vitro [32], and it has also
been shown to link with endothelial dysfunction in those
with hypertension. Perhaps most importantly, uric acid
has a putative role in the development of hypertension
[33–35]v i ae ﬀects on nitric oxide production in the
macula densa. Studies have shown that uric acid reduc-
tion with allopurinol can improve blood pressure in ado-
lescents with newly diagnosed hypertension as discussed
later.
5.UricAcidIsProtective
It is clear that our life span has increased markedly during
evolution and this may in part reﬂect a reduction in early
cancer rates compared to other mammalian species. It has
been argued that this is due to evolution of more eﬀective
antioxidant mechanisms and that higher levels of serum
uric acid are a key component of such mechanisms [24].
Given that uric acid is the most abundant antioxidant in
plasma, it is feasible that this change in uric acid metabolism
has been key to our prolonged survival. This is supported
by an elegant series of experiments suggesting that uric
acid does indeed protect against oxidative damage and is
as eﬀective as ascorbic acid [24]. Paradoxically, however,
focus has now shifted to an accusatory role for uric acid in
disease.
Uric acid has been shown to have antioxidant activity
in humans, and the rising levels that have accompanied
human evolution may thus have been beneﬁcial and have
increased longevity. This hypothesis is further supported by
data showing that in healthy human volunteers, uric acid
administration increases total serum antioxidant capacity
[36] and reduces oxidative stress associated with exer-
cise.
There is also evidence that serum uric acid levels increase
after an ischaemic insult and many argue that elevated serum
uric acid represents a physiological and protective response
to oxidative stress and acute vascular insults [37, 38].
This hypothesis is supported by the previously mentioned
study where increasing serum uric acid levels linked with a
good clinical outcome [8] and other surrogate markers of
outcome. In a rat model of cerebral ischaemia, brain uric
acid levels have been shown to increase [39, 40], and in
a transient ischaemia model, infusion of uric acid led to
a reduction of infarct volume and improved behavioural
outcome [40] suggesting therapeutic potential for infusion
of serum uric acid. Similar ﬁndings were demonstrated in
models of traumatic brain injury and multiple sclerosis [41,
42]. Data from twin studies also suggest that uric acid may
be beneﬁcial for the brain; levels of uric acid in suﬀerers of
multiplesclerosishavebeenfoundtobelowerthaninhealthy
siblings [43].
Recently, the therapeutic potential of uric acid adminis-
tration after stroke has been explored in humans. In a small
study of individuals treated with intravenous thrombolytic
therapy, intravenous infusion of uric acid in the early period
after ischaemic stroke reduced markers of oxidative stress
[44].
6. AlternativeExplanations—The
InnocentBystander
It is argued that the apparent link between serum uric acid
and disease simply reﬂects the presence of other risk factors.
For example, serum uric acid is known to link and cluster
with other risk factors, and it may be that atherosclerosis
itself or increased oxidative stress leads to increased serum
uric acid hence the apparent association.
Worsening renal function is associated with both
increased serum uric acid levels and increased burden of car-
diovascular disease, although most epidemiological studies
have adequately attempted to adjust for renal impairment.
High levels of serum uric acid link with presence of obesity,
adverse lipid proﬁles, including low HDL levels, and insulin
resistance [45–47]. As mentioned there is an association with
blood pressure, and uric acid has been implicated in the
development of hypertension [48, 49] and use of allopurinol
has led to falls in blood pressure in adolescents with newly
diagnosed hypertension [49].
It is also possible that higher levels of uric acid may
reﬂecthigherlevelsofxanthineoxidaseactivityandoxidative
stress. The action of xanthine oxidase leads to generation
of superoxide anions and is one of the principle sources
of reactive oxygen species (ROS) in the human vasculature
[50, 51]. The molecular eﬀects and importance of ROS in
cardiovascular disease has already been extensively reviewed
[52–55]. Traditionally, xanthine oxidase has been considered
signiﬁcantly less important than NADPH oxidase as a source
of oxidative stress in the vasculature. Emerging evidence
suggests that the reverse may be more representative of the in
vivo situation. Studies suggest that xanthine oxidase activity
isgreatlyincreasedinthosewithheartfailureandinresponse
to ischaemia [1, 2]. On a practical level, potential for clinical
relevance is much greater; a licensed and commonly used
inhibitor of xanthine oxidase exists, which of course is not
the case for NADPH oxidase.
Thus, regardless of whether serum uric acid itself is
harmful, it could still prove to be a powerful marker of
a high-risk disease state by helping identify those with
increased xanthine oxidase activity which, via oxidative
stress, may directly contribute to the development of
atherosclerotic disorders and vascular events.
7.DoesLoweringSerumUricAcidModify
CardiovascularRisk(withAgents
Other thanXanthineOxidaseInhibitors)?
There are no adequately powered clinical endpoint trials of
uric acid lowering strategies. However, three drugs known to
reduce cardiovascular mortality have been shown to reduce
serum uric acid, which, hypothetically, may explain some of
their beneﬁcial eﬀect.
Fenoﬁbrate lowers triglyceride and total and LDL choles-
t e r o ll e v e l sa n di n c r e a s e sH D Lc h o l e s t e r o l[ 56]. It also
reduces serum uric acid level (via increased renal excretion)
by as much as 46% in healthy volunteers and hypertensive
and diabetic patients and has an eﬀect additive to other4 Cardiovascular Psychiatry and Neurology
urate lowering therapies [57–59]. Losartan is an angiotensin
II receptor antagonist known to reduce serum uric acid
levels by as much as 30% [60], via increased renal uric
acid excretion [61]. Nearly a third of the modest relative
risk reduction seen with losartan use in the LIFE study
[62] has been attributed to its eﬀect on serum uric acid
[63]. As a further example, atorvastatin has been shown
to reduce serum uric acid (by approximately 8%), even
after adjustment for risk factors including change in renal
function. Each 60µmol/L reduction in serum uric acid
following atorvastatin use was associated with a reduction in
vascular event rates (HR 0.76, 95% CI 0.62–0.89) [64].
In addition to these large trials, the eﬀect of Probenecid
(a uricosuric agent with no eﬀect on xanthine oxidase) has
been studied in a a group with heart failure. In a randomised
crossover design, Probenecid 500mg bid for three weeks
reduceduricacid(to0.25mmol/L)incomparisontoplacebo
(where it remained increased at 0.44mmol/L). This reduc-
tion was similar to that observed with allopurinol 300mg od
overthreeweeksbutnoimprovementinendothelialfunction
wasseen(whereasitwaswithallopurinol)suggestingthatthe
mechanismofbeneﬁtofallopurinolisuricacid-independent
[65].
8.Does XanthineOxidaseInhibitionModify
CardiovascularRisk?
Recent relevant clinical research has focussed on the use of
the xanthine oxidase inhibitors allopurinol and oxypurinol
in the prevention of cardiovascular diseases. Allopurinol
is a structural analogue of hypoxanthine and is rapidly
metabolised to oxypurinol, which functions similarly. They
preferentially bind to xanthine oxidase thereby inhibiting its
activity[66].Thiswillloweruricacidlevelsbutalsoxanthine
oxidase mediated free radical production. Furthermore,
there is evidence that the drug has a direct scavenging eﬀect
on free radicals.
The eﬀect of xanthine oxidase inhibition on measures of
endothelial and cardiovascular function has been tested in
small studies of those with heart failure, coronary artery dis-
ease, stroke, diabetes, hypertension, hypercholesterolaemia,
smokers, elevated 10-year cardiovascular risk, metabolic
syndrome, COPD, sleep apnoea, the elderly, and in those
with chronic liver disease [65, 67–100]. The ﬁndings of these
are summarised below in order of the endpoints assessed.
8.1. Endothelial Function and Oxidative Stress. Improvement
inendothelialfunctionhasbeenobservedfollowingxanthine
oxidase inhibition in patients with heart failure [65, 69, 70],
coronary artery disease [75, 90], diabetes [78], hypercholes-
terolaemia[81],smokers[83,95],highoverallcardiovascular
risk [84], metabolic syndrome [85], obstructive sleep apnoea
[86], and stroke [87].
In some studies beneﬁt has been restricted to those with
hyperuricaemic [69, 84]. Also, some studies have found
no improvement following xanthine oxidase inhibition in
healthy subjects [96], patients with hypertension [81], and
a group with hypercholesterolaemia [82]. Further, it is a
consistent ﬁnding that those included in healthy control
groups show no beneﬁt from xanthine oxidase inhibition
[78, 81, 83, 95, 96].
Levels of oxidative stress in the circulation have been
shown to reduce in response to xanthine oxidase inhi-
bition in subjects with heart failure [69, 70], diabetes
[79], metabolic syndrome [85], obstructive sleep apnoea
[86], coronary artery disease [88, 90], chronic obstructive
pulmonary disease [96, 97], and liver disease [99]. Markers
of oxidative stress did not reduce in some studies of healthy
volunteers [96] and in those with diabetes [80], and again, in
healthy control arms of many studies, no beneﬁt was seen.
These diﬀering results may be accounted for by diﬀer-
ences in study design (in particular small sample size and
baseline subject characteristics). A further consideration is
the potential for beneﬁt in those who do not have signiﬁcant
impairment of vascular function. As mentioned, data are less
compelling in those with only vascular risk factors but no
established disease and in healthy control arms. Xanthine
oxidase may have a limited role in determining endothelial
function in those with a “healthy” vascular system, and
indeed, evidence exists to suggest that enzyme activity is
increasedduringstressessuchasischaemia[1].Furthermore,
xanthine oxidase may not be universally integral to endothe-
lial dysfunction in all cardiovascular disease conditions.
Another intriguing ﬁnding from some studies is that
beneﬁt may be limited to those with hyperuricaemia only,
perhaps because hyperuricaemia reﬂects pathological levels
of enzyme activity.
8.2. Haemodynamic/Cardiac Outcomes. Improvement in
blood pressure has been reported following xanthine oxidase
inhibition [91, 93, 94].
Improvement in cardiac function, including left ven-
tricular ejection fraction [72, 76, 88], cardiac index [88],
end-systolic volume [76], and myocardial eﬃciency [67]h a s
been documented in those with cardiac failure, although
no diﬀerence in heart rate, dysrhythmia count [68]o r
exercise capacity was found [71–73]. A reduction in “infarct
extension” has been reported in an allopurinol treatment
group in the acute coronary syndrome setting, though
methodological considerations make interpretation of this
ﬁnding diﬃcult [89].
Long-term outcomes in response to xanthine oxidase
inhibition have been assessed in those with heart failure.
A medium-sized prospective study identiﬁed no overall
diﬀerence following oxypurinol treatment upon a combined
outcome of heart failure-related mortality/morbidity/quality
of life but did suggest potential beneﬁt amongst hyper-
uricaemic patients [73]. One large retrospective analysis
suggested a protective eﬀect with high-dose allopurinol over
low-dose treatment [100]. Intriguingly the study found that
low-dose allopurinol was associated with a poorer outcome
compared with no treatment at all. The retrospective study
design does not permit a deﬁnitive explanation for this
paradox but perhaps lends further weight to the concept that
the interplay between uric acid level and xanthine oxidase
activityandvascularhealthiscomplexandachievingoptimal
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8.3. Humoral/Inﬂammatory Indices. Some studies have
shown an improvement in renal function [92, 94] following
allopurinol use. C reactive protein, a surrogate marker for
chronic inﬂammation, has also been found to reduce in
response to treatment [94], though this ﬁnding has not
been reproduced in other studies [65, 71, 77, 85]. The
above noted improvements in cardiac physiology have been
supplemented by the ﬁnding that brain natriuretic peptide, a
prognostic indicator in heart failure, reduced in one study
[71]. One study identiﬁed a reduction in cholesterol with
allopurinol versus placebo, P<. 05 [71], though this ﬁnding
is yet to be reproduced.
In those with recent stroke, we have shown that use
of allopurinol attenuates the rise in inﬂammatory markers
seen after stroke [77] and also that it improves basal
levels of cerebrovascular nitric oxide in those with diabetes
[101]. In this study, the response to infusion of NG-
Monomethyl-L-Arginine (L-NMMA) was assessed; in the
cerebral vasculature, L-NMMA reduces cerebral blood ﬂow
through restriction of NO activity, and the higher the basal
NO activity, the larger the eﬀect. Allopurinol enhanced this
eﬀect implying that it improves basal levels of NO activity
and the response improved towards levels seen in healthy
volunteers.
However, we must acknowledge that results from the
largest study to date were disappointing. In the OPT-
CHF trial [73], 405 participants with heart failure were
randomised to receive either oxypurinol 600mg or placebo
for 6 months. The primary endpoint was deﬁned as a
change in clinical status based upon changes in a variety
of clinical parameters including mortality and common
measures of heart failure severity. There was no diﬀerence
in the proportion of patients who improved or worsened
between treatment groups (43.3% improved with allop-
urinol compared to 45%) with placebo while 32% and
35.6% remained the same and 24.6% and 19.3% worsened
(P = .42). However, posthoc analyses suggested that in those
with elevated serum uric acid, oxypurinol improved clinical
status, whereas the opposite occurred in those with lower
uric acid levels. In the oxypurinol cohort as a whole, those
who improved had signiﬁcantly greater reductions in serum
uric acid levels than those who worsened. These ﬁndings
are diﬃcult to interpret. On one hand the posthoc analyses
suggest beneﬁt in those with high uric acid levels and that
the greater the fall following oxypurinol in such patients,
the better the outcome; they also raise the possibility that
oxypurinol can cause harm in some.
9.Hypothesis—IsUricAcid Good,Bad,
or Indifferent?
The epidemiological evidence does suggest that elevated
serum uric acid links with increased incidence and severity
of a variety of cardiovascular diseases; yet we know that it
has antioxidant properties, and small preclinical and clinical
studies suggest that serum uric acid may be neuroprotective.
However, data do exist to support detrimental and pro-
thrombotic eﬀects of uric acid on platelet and endothelial
function, and an ever growing number of clinical studies
suggest that uric acid lowering strategies do reduce vascular
risk, although for the most part the evidence concerns use of
allopurinol which may have other beneﬁcial eﬀects; xanthine
oxidasemediatedoxidativestressislikelytohaveasigniﬁcant
role in the development of atherosclerosis.
It is important to note that these hypotheses are not
mutually exclusive. Firstly, increased local tissue levels of
uric acid in ischaemia and brain injury may reﬂect levels of
oxidative stress and xanthine oxidase activity and thus the
mechanism of harm and not an innate protective response.
Essentially, the substance itself may well have antioxidant
properties but its generation and associated superoxide
anion production may be of much greater signiﬁcance
and detriment in the longer term. Thus, the antioxidant
properties of uric acid could well be harnessed to improve
clinical outcomes in the acute phase of cardiovascular and
neurological illness. Furthermore, the measurement of uric
acid levels in those at risk of disease may identify those
at high risk who may beneﬁt from treatments such as
allopurinol, either because of uric acid itself or because
of xanthine oxidase activity and oxidative stress. Perhaps
data from the OPT-CHF study support these seemingly
competing views; beneﬁt from uric acid reduction may
only be seen in those with serum uric acid high enough
to harm platelet and endothelial function while uric acid
reduction in those with lower levels may compromise
plasma oxidant activity such that this could be of detri-
ment.
10. Summary
There is a now a wealth of epidemiological, animal, and now
clinical data to suggest the beneﬁts of strategies to lower
uric acid and inhibit xanthine oxidase. Large scale trials
with clinical endpoints are justiﬁed to address this important
question and to deﬁne treatment thresholds and targets and
to clarify if beneﬁt is real.
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